April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
A new artificial tear testing in New Zeland Rabbits
Author Affiliations & Notes
  • Yussett Contreras
    Medical Research Department, Laboratorios Sophia SA de CV, Zapopan, Mexico
  • Oscar Olvera
    Medical Research Department, Laboratorios Sophia SA de CV, Zapopan, Mexico
  • Paloma Astrid Marquez
    Medical Research Department, Laboratorios Sophia SA de CV, Zapopan, Mexico
  • Leopoldo M Baiza-Duran
    Medical Research Department, Laboratorios Sophia SA de CV, Zapopan, Mexico
  • Paulina Melgarejo
    Medical Research Department, Laboratorios Sophia SA de CV, Zapopan, Mexico
  • Jonathan Bonilla
    Medical Research Department, Laboratorios Sophia SA de CV, Zapopan, Mexico
  • Gabriela Fregoso
    Medical Research Department, Laboratorios Sophia SA de CV, Zapopan, Mexico
  • Footnotes
    Commercial Relationships Yussett Contreras, Laboratorios Sphia SA de CV (E); Oscar Olvera, Laboratorios Sophia SA de CV (E); Paloma Marquez, Laboratorios Sophia SA de CV (E); Leopoldo Baiza-Duran, Laboratorios Sophia SA de CV (E); Paulina Melgarejo, Laboratorios Sophia SA de CV (E); Jonathan Bonilla, Laboratorios Sophia SA de CV (E); Gabriela Fregoso, Laboratorios Sophia SA de CV (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6300. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yussett Contreras, Oscar Olvera, Paloma Astrid Marquez, Leopoldo M Baiza-Duran, Paulina Melgarejo, Jonathan Bonilla, Gabriela Fregoso, ; A new artificial tear testing in New Zeland Rabbits. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6300.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate clinical and histopathological safety of a new artificial tear, chondroitin sulfate + xanthan gum (CX) applied on ocular surface of New Zealand rabbits.

Methods: The study was conducted under ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Sixteen rabbits were assessed. 16 eyes received CX and 16 eyes received placebo. The instillation was scheduled every two hours between 7 and 19 hrs during 15 days. Clinical assessment was accomplished on days 0 (baseline), 1, 2, 4, 7, 10 and 15. Safety parameters: conjunctival hyperemia, chemosis, corneal surface integrity, conjunctival secretion, Rose Bengal and fluorescein staining. On days 0 and 15, fundoscopy was performed under pharmacological mydriasis. At day 16, all rabbits where sacrificed and enucleated. A blind histopathological study was executed and the tissues were examined in order to determine: cornea (changes in the epithelial thickness, basal membrane integrity, cellular changes), conjunctiva (presence of goblet cells, apoptosis, diskeratinization).

Results: Thirty-two eyes were assessed. Both groups had no pathological findings in the posterior segment, ciliary injection or fundus in the study. Two cases present of conjunctival hyperemia in the CX group (day 2 and 4), less than 25% of total conjuntival area. Chemosis in both groups was observed during the study. The percentage cases of chemosis was greater in the placebo group than in the CX group. CX group had a higher percentage of secretion, although, hyaline/whitish/crystal conjunctival discharge was in CX group and placebo group had cases of yellow/ green discharge. Of all sample, only one eye had altered corneal surface, which belonged to CX group as a valuation day 1, presenting corneal stippling. Any groups showed uptake Rose Bengal dye on the corneal surface. Both study groups showed uptake of fluorescein dye in the corneal surface of the eye by evaluating the day 1 until the end of follow-up, all cases were stained with score 1. There were no statistically significant intergroup differences. In both groups no cytological toxicity changes were found

Conclusions: The safety parameters evaluated in the study showed that the polimer combination in CX is clinical and histopathological safe and no toxic when is compared with placebo group and applied to the ocular surface of New Zealand rabbits.

Keywords: 486 cornea: tears/tear film/dry eye • 503 drug toxicity/drug effects • 480 cornea: basic science  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×